Analysts Offer Predictions for Microbot Medical Inc.’s Q1 2024 Earnings (NASDAQ:MBOT)

Microbot Medical Inc. (NASDAQ:MBOT) – HC Wainwright boosted their Q1 2024 earnings estimates for shares of Microbot Medical in a research note issued to investors on Tuesday, April 16th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings of ($0.17) per share for the quarter, up from their prior forecast of ($0.19). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Microbot Medical’s Q2 2024 earnings at ($0.16) EPS, Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.13) EPS and FY2024 earnings at ($0.61) EPS.

Microbot Medical Stock Down 5.1 %

Microbot Medical stock opened at $0.90 on Thursday. The company’s 50-day moving average price is $1.21 and its 200-day moving average price is $1.29. Microbot Medical has a twelve month low of $0.88 and a twelve month high of $4.37. The company has a market cap of $12.96 million, a PE ratio of -0.83 and a beta of 1.64.

Institutional Trading of Microbot Medical

Large investors have recently made changes to their positions in the business. Wells Fargo & Company MN increased its holdings in shares of Microbot Medical by 6,713.4% in the 2nd quarter. Wells Fargo & Company MN now owns 12,741 shares of the biotechnology company’s stock worth $35,000 after buying an additional 12,554 shares during the last quarter. Hilltop Holdings Inc. bought a new position in Microbot Medical during the 2nd quarter valued at about $52,000. Virtu Financial LLC grew its holdings in Microbot Medical by 75.9% during the 4th quarter. Virtu Financial LLC now owns 42,046 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 18,138 shares during the last quarter. Cetera Advisor Networks LLC bought a new position in Microbot Medical during the 1st quarter valued at about $78,000. Finally, Renaissance Technologies LLC grew its holdings in Microbot Medical by 52.5% during the 1st quarter. Renaissance Technologies LLC now owns 15,695 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 5,400 shares during the last quarter. 16.30% of the stock is currently owned by institutional investors.

Microbot Medical Company Profile

Microbot Medical Inc operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.